Deutsche Bank Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €81.00 Price Target

Deutsche Bank set a €81.00 ($96.43) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Tuesday, May 8th. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Warburg Research set a €80.00 ($95.24) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, April 23rd. Barclays set a €81.00 ($96.43) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, February 2nd. Kepler Capital Markets set a €63.00 ($75.00) target price on Fresenius SE & Co KGaA and gave the stock a neutral rating in a research report on Monday, April 23rd. Cfra set a €76.00 ($90.48) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Friday, May 4th. Finally, Commerzbank set a €79.00 ($94.05) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, April 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of €76.94 ($91.59).

Fresenius SE & Co KGaA stock opened at €67.04 ($79.81) on Tuesday. Fresenius SE & Co KGaA has a one year low of €60.16 ($71.62) and a one year high of €80.00 ($95.24).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply